Logo der Universität Basel

Research Database / FORSCHUNGSDATENBANK 
PRINTDOC
 
Publication 1195224 | Verified
 

Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
KRAS and BRAF mutation analysis in metastatic colorectal cancer : a cost-effectiveness analysis from a Swiss perspective
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1195224
Author(s) Blank, Patricia R; Moch, Holger; Szucs, Thomas D; Schwenkglenks, Matthias
Author(s) at UniBasel Blank, Patricia R.
Schwenkglenks, Matthias
Year 2011
Title KRAS and BRAF mutation analysis in metastatic colorectal cancer : a cost-effectiveness analysis from a Swiss perspective
Journal Clinical cancer research
Volume 17
Number 19
Pages / Article-Number 6338-46
Abstract Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients.
Publisher American Association for Cancer Research
ISSN/ISBN 1078-0432
edoc-URL http://edoc.unibas.ch/dok/A6005410
Full Text on edoc No
Digital Object Identifier DOI 10.1158/1078-0432.CCR-10-2267
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/21807639
ISI-Number WOS:000295457900025
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.332 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/05/2024